113 related articles for article (PubMed ID: 29608954)
1. Hybrid nanoparticles as a new technological approach to enhance the delivery of cholesterol into the brain.
Belletti D; Grabrucker AM; Pederzoli F; Menrath I; Vandelli MA; Tosi G; Duskey TJ; Forni F; Ruozi B
Int J Pharm; 2018 May; 543(1-2):300-310. PubMed ID: 29608954
[TBL] [Abstract][Full Text] [Related]
2. Insight on the fate of CNS-targeted nanoparticles. Part II: Intercellular neuronal cell-to-cell transport.
Tosi G; Vilella A; Chhabra R; Schmeisser MJ; Boeckers TM; Ruozi B; Vandelli MA; Forni F; Zoli M; Grabrucker AM
J Control Release; 2014 Mar; 177():96-107. PubMed ID: 24417968
[TBL] [Abstract][Full Text] [Related]
3. Investigation on mechanisms of glycopeptide nanoparticles for drug delivery across the blood-brain barrier.
Tosi G; Fano RA; Bondioli L; Badiali L; Benassi R; Rivasi F; Ruozi B; Forni F; Vandelli MA
Nanomedicine (Lond); 2011 Apr; 6(3):423-36. PubMed ID: 21542682
[TBL] [Abstract][Full Text] [Related]
4. Impact of surfactants on the target recognition of Fab-conjugated PLGA nanoparticles.
Kennedy PJ; Perreira I; Ferreira D; Nestor M; Oliveira C; Granja PL; Sarmento B
Eur J Pharm Biopharm; 2018 Jun; 127():366-370. PubMed ID: 29549023
[TBL] [Abstract][Full Text] [Related]
5. Potential use of polymeric nanoparticles for drug delivery across the blood-brain barrier.
Tosi G; Bortot B; Ruozi B; Dolcetta D; Vandelli MA; Forni F; Severini GM
Curr Med Chem; 2013; 20(17):2212-25. PubMed ID: 23458620
[TBL] [Abstract][Full Text] [Related]
6. Insight on the fate of CNS-targeted nanoparticles. Part I: Rab5-dependent cell-specific uptake and distribution.
Vilella A; Tosi G; Grabrucker AM; Ruozi B; Belletti D; Vandelli MA; Boeckers TM; Forni F; Zoli M
J Control Release; 2014 Jan; 174():195-201. PubMed ID: 24316476
[TBL] [Abstract][Full Text] [Related]
7. EXPLOITING THE VERSATILITY OF CHOLESTEROL IN NANOPARTICLES FORMULATION.
Belletti D; Grabrucker AM; Pederzoli F; Menrath I; Cappello V; Vandelli MA; Forni F; Tosi G; Ruozi B
Int J Pharm; 2016 Sep; 511(1):331-340. PubMed ID: 27418565
[TBL] [Abstract][Full Text] [Related]
8. Tissue inhibitor of matrix metalloproteinases-1 loaded poly(lactic-co-glycolic acid) nanoparticles for delivery across the blood-brain barrier.
Chaturvedi M; Molino Y; Sreedhar B; Khrestchatisky M; Kaczmarek L
Int J Nanomedicine; 2014; 9():575-88. PubMed ID: 24531257
[TBL] [Abstract][Full Text] [Related]
9. Characterization of lysosome-destabilizing DOPE/PLGA nanoparticles designed for cytoplasmic drug release.
Chhabra R; Grabrucker AM; Veratti P; Belletti D; Boeckers TM; Vandelli MA; Forni F; Tosi G; Ruozi B
Int J Pharm; 2014 Aug; 471(1-2):349-57. PubMed ID: 24882034
[TBL] [Abstract][Full Text] [Related]
10. PLGA nanoparticles for peroral delivery: How important is pancreatic digestion and can we control it?
Mante A; Heider M; Zlomke C; Mäder K
Eur J Pharm Biopharm; 2016 Nov; 108():32-40. PubMed ID: 27553262
[TBL] [Abstract][Full Text] [Related]
11. Improved delivery of the natural anticancer drug tetrandrine.
Shi C; Ahmad Khan S; Wang K; Schneider M
Int J Pharm; 2015 Feb; 479(1):41-51. PubMed ID: 25510598
[TBL] [Abstract][Full Text] [Related]
12. Development of zolmitriptan loaded PLGA/poloxamer nanoparticles for migraine using quality by design approach.
Girotra P; Singh SK; Kumar G
Int J Biol Macromol; 2016 Apr; 85():92-101. PubMed ID: 26724690
[TBL] [Abstract][Full Text] [Related]
13. Preparation and characterization of teniposide PLGA nanoparticles and their uptake in human glioblastoma U87MG cells.
Mo L; Hou L; Guo D; Xiao X; Mao P; Yang X
Int J Pharm; 2012 Oct; 436(1-2):815-24. PubMed ID: 22846410
[TBL] [Abstract][Full Text] [Related]
14. Effects of surface modification of PLGA-PEG-PLGA nanoparticles on loperamide delivery efficiency across the blood-brain barrier.
Chen YC; Hsieh WY; Lee WF; Zeng DT
J Biomater Appl; 2013 Mar; 27(7):909-22. PubMed ID: 22207601
[TBL] [Abstract][Full Text] [Related]
15. Effects of surfactants on the properties of PLGA nanoparticles.
Menon JU; Kona S; Wadajkar AS; Desai F; Vadla A; Nguyen KT
J Biomed Mater Res A; 2012 Aug; 100(8):1998-2005. PubMed ID: 22566409
[TBL] [Abstract][Full Text] [Related]
16. Brain targeting with surface-modified poly(D,L-lactic-co-glycolic acid) nanoparticles delivered via carotid artery administration.
Tahara K; Miyazaki Y; Kawashima Y; Kreuter J; Yamamoto H
Eur J Pharm Biopharm; 2011 Jan; 77(1):84-8. PubMed ID: 21074612
[TBL] [Abstract][Full Text] [Related]
17. PLGA nanoparticles prepared by nano-emulsion templating using low-energy methods as efficient nanocarriers for drug delivery across the blood-brain barrier.
Fornaguera C; Dols-Perez A; Calderó G; García-Celma MJ; Camarasa J; Solans C
J Control Release; 2015 Aug; 211():134-43. PubMed ID: 26057857
[TBL] [Abstract][Full Text] [Related]
18. Preparation and in vitro evaluation of thienorphine-loaded PLGA nanoparticles.
Yang Y; Xie XY; Mei XG
Drug Deliv; 2016; 23(3):787-93. PubMed ID: 24870204
[TBL] [Abstract][Full Text] [Related]
19. Surface modified PLGA nanoparticles for brain targeting of Bacoside-A.
Jose S; Sowmya S; Cinu TA; Aleykutty NA; Thomas S; Souto EB
Eur J Pharm Sci; 2014 Oct; 63():29-35. PubMed ID: 25010261
[TBL] [Abstract][Full Text] [Related]
20. Insights into kinetics, release, and behavioral effects of brain-targeted hybrid nanoparticles for cholesterol delivery in Huntington's disease.
Birolini G; Valenza M; Ottonelli I; Passoni A; Favagrossa M; Duskey JT; Bombaci M; Vandelli MA; Colombo L; Bagnati R; Caccia C; Leoni V; Taroni F; Forni F; Ruozi B; Salmona M; Tosi G; Cattaneo E
J Control Release; 2021 Feb; 330():587-598. PubMed ID: 33412229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
